Ursodeoxycholic acid has not been associated with the liver damage; however, measure AST and ALT at initiation of and during therapy as indicated by particular clinical circumstances.
Monitoring: perform ultrasound images of gall bladder at 6-month intervals for first year of therapy to monitor gallstone response. If partial stone dissolution is not seen by 12 months of therapy, likelihood of success is greatly reduced.